Patent application number | Description | Published |
20090233285 | SPECIFIC METHOD OF PROSTATE CANCER DETECTION BASED ON PCA3 GENE, AND KITS THEREFOR - The present invention relates, in general, to prostate cancer. More specifically, the present invention relates to a method to diagnose prostate cancer in a patient by detecting a PCA3 sequence, and more particularly a PCA3 RNA, the PCA3 sequence detected in a sample from the patient being specifically associated with prostate cancer. In a particular embodiment the method and kit enables an amplification of a PCA3 RNA through an exon-exon junction of a spliced PCA3 mRNA. The invention also relates to methods and kits to detect such an amplified PCA3 RNA, using a probe which spans the amplified exon-exon junction. In particular the methods and kits are designed to detect a PCA3 RNA which lacks one intron or more, and in particular case is intron-less. The invention further relates to a method of detecting PCA3 RNA expressed in non-prostate tissue or cells of the urinary tract, that comprises PCA3 intron 3. | 09-17-2009 |
20110165178 | DIAGNOSIS OF PROSTATE CANCER - The present invention relates to vitro diagnosis methods of prostate cancer from a test biological sample, comprising measuring the expression level of KIAA0153 in said test biological sample, as well as to methods for screening compounds inhibiting KIAA0153 gene expression or biological activity and uses of such KIAA0153 inhibiting compounds. | 07-07-2011 |
20120108453 | MOLECULAR MARKERS IN PROSTATE CANCER - The present invention relates to methods for diagnosing prostate cancer and especially diagnosing LG, i.e., individuals with good prognosis; HG, i.e., individuals with poor prognosis of primary tumour; PrCa Met, i.e., individuals with poor prognosis and metastasis; and CRPC, i.e., individuals with poor prognosis suffering from aggressive localized disease. Specifically, the present invention relates to method for establishing the presence, or absence, of prostate cancer in a human individual comprising: a) determining the expression of one or more genes chosen from the group consisting of RRM2, HOXC6, TGM4, RORB, HOXDlO, SFRP2, and SNAI2 in a sample originating from said human individual; b) establishing up, or down, regulation of expression of said one or more genes as compared to expression of said respective one or more genes in a sample originating from said human individual not comprising prostate tumour cells or prostate tumour tissue, or from an individual not suffering from prostate cancer; and c) establishing the presence, or absence, of prostate cancer based on the established up- or down regulation of said one or more genes. | 05-03-2012 |
20120142553 | Molecular Markers in Kidney Cancer - The present invention relates to methods for establishing the presence, or absence, of a kidney, or renal, tumour in a human individual suspected of suffering from kidney, or renal, cancer. Specifically, the present invention relates to methods for establishing the presence, or absence, of a kidney tumour in a human individual suspected of suffering from kidney cancer comprising: a) determining the expression of one or more genes chosen from the group consisting of NDUFA4l2, ANGPTL4, EGLN3, PTHLH, and ATP6V1B1 in a sample originating from said human individual; b) establishing up, or down, regulation of expression of said one or more genes as compared to expression of said respective one or more genes in a sample originating from said human individual not comprising kidney tumour cells or tissue, or from an individual, or group of individuals, not suffering from kidney cancer; and c) establishing the presence, or absence, of a kidney tumour based on the established up- or down regulation of said one or more genes. | 06-07-2012 |
20120309006 | SPECIFIC METHOD OF PROSTATE CANCER DETECTION BASED ON PCA3 GENE, AND KITS THEREFOR - The invention relates to a method to diagnose prostate cancer by detecting a PCA3 sequence. In one embodiment the method and kit enables amplification of PCA3 RNA through an exon-exon junction of a spliced PCA3 mRNA, and methods and kits to detect an amplified PCA3 RNA, using a probe which spans the amplified exon-exon junction. The methods and kits can detect a PCA3 RNA lacking one intron or more. Also provided are methods of detecting PCA3 RNA expressed in non-prostate tissue or cells of the urinary tract, which comprises PCA3 intron 3. In addition, methods are provided to determine whether a sample from a subject contains or lacks prostate cells, by performing a hybridization and/or amplification reaction on RNA from the sample to detect the presence or level of PCA3 RNA that lacks at least one intron and distinguishing a prostate cell from a non-prostate cell. | 12-06-2012 |
20120309007 | PROSTATE CANCER PROGNOSTIC COMPOSITIONS AND KITS - Described herein are method, compositions and kits for prognosis of prostate cancer. The methods comprise: determining the ratio of PCA3 and of a prostate-specific marker expression in a urine sample and correlating the value of the PCA3/prostate-specific marker ratio with the aggressiveness and mortality risk of prostate cancer in the subject. The present invention features a method for prognosing prostate cancer in a sample of a patient comprising: assessing the amount of a prostate cancer specific PCA3 mRNA and the amount of prostate-specific marker in the sample; determining a ratio value of this amount of prostate cancer specific PCA3 mRNA over the amount of prostate-specific marker; comparing the ratio value to at least one predetermined cut-off value, wherein a ratio value above the predetermined cut-off value is indicative of a higher risk of mortality of prostate cancer as compared to a ratio value below the predetermined cut-off value. | 12-06-2012 |
20130261171 | PROSTATE CANCER PROGNOSTIC COMPOSITIONS AND KITS - Described herein are method, compositions and kits for prognosis of prostate cancer. The methods include determining the ratio of PCA3 and of a prostate-specific marker expression in a urine sample and correlating the value of the PCA3/prostate-specific marker ratio with the aggressiveness and mortality risk of prostate cancer in the subject. The method for prognosing prostate cancer in a sample of a patient includes assessing the amount of a prostate cancer specific PCA3 mRNA and the amount of prostate-specific marker in the sample; determining a ratio value of this amount of prostate cancer specific PCA3 mRNA over the amount of prostate-specific marker; comparing the ratio value to at least one predetermined cut-off value, wherein a ratio value above the predetermined cut-off value is indicative of a higher risk of mortality of prostate cancer as compared to a ratio value below the predetermined cut-off value. | 10-03-2013 |
20150017640 | Combinations of Molecular Markers in Prostate Cancer providing a Diagnostic Tool with Improved Sensitivity/Specificity - The present invention relates to methods for in vitro establishing, or diagnosing, high grade or low grade prostate cancer in a sample, preferably from a readily obtainable sample such as an urine, a prostatic fluid or ejaculate sample or a processed, or derived sample thereof, originating from human individual suspected of suffering from prostate cancer using expression level analysis of a combination of two, or three molecular markers for prostate cancer selected from DLX1, HOXC6 and HOXD10. The present invention further relates to the use in expression level analysis of these combined markers for in vitro establishing high grade or low grade prostate cancer and to a kit of parts providing expression analysis of combinations of the present molecular markers for establishing high grade or low grade prostate cancer. | 01-15-2015 |